Astrazenica’s 570,000-square-foot lease at 290 Binney St. in Cambridge represents the first tenant to commit to Boston Properties’ mixed-use redevelopment of its Blue Garage property in Kendall Square, while potentially creating new opportunities for life science companies to grow in Boston’s Seaport District and Waltham.
Cambridge-based Foundation Medicine has signed the biggest commercial lease in Boston’s Seaport District in eight years, consolidating 1,100 employees at 400 Summer St. and giving new momentum to the neighborhood’s growing life science cluster.
A speculative Seaport District office tower that attracted headquarters locations by Alexion Pharmaceuticals and PTC has been sold to Norges Bank Real Estate Management and American Realty Advisors for $455 million.
A merger between the second and sixth largest employers in Massachusetts’ all-important life science industry typically would cause indigestion in commercial real estate and economic development circles.
Developer Skanska has completed construction of a walking museum between its 101 and 121 Seaport office towers including historical exhibits on the neighborhood’s marine industrial past.
High-ranking corporate executives in the financial, tech, real estate and health care industries are well-represented in the initial round of buyers at 50 Liberty, the newly opened 120-unit luxury condo tower on Boston’s Fan Pier.
We designed 121 Seaport as a highly flexible, ultra-efficient building with amenities and collaborative indoor and outdoor spaces that we knew would attract market leaders like PTC.
Connecticut-based Alexion Pharmaceuticals will move its headquarters from New Haven to Boston’s Seaport District in mid-2018, bringing 400 corporate and research jobs and filling the remaining office and lab space in a speculative tower scheduled to open early next year.
